))
403. I-CAN, A Study of Inebilizumab in Children with AQP4+ NMOSD
Manage episode 376260563 series 3240321
Content provided by Siegel Rare Neuroimmune Association (SRNA). All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Siegel Rare Neuroimmune Association (SRNA) or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
For this “ABCs of NMOSD” episode, Rebecca Whitney of SRNA was joined by Dr. Michael Levy. Dr. Levy gave an overview of I-CAN, a Phase 2 study of inebilizumab in children with aquaporin-4 positive neuromyelitis optica spectrum disorder or NMOSD. As one of the principal investigators for the study, he shared details about inclusion criteria and inebilizumab, brand name Uplizna™. Dr. Levy also discussed what someone can expect if they choose to participate in this trial, how participation would impact someone’s current treatment, and the timeline of this trial. Additional information is available here:
https://clinicaltrials.gov/study/NCT05549258?term=NCT05549258&aggFilters=status:not%20rec&rank=1
31 episodes
Share
